This HTML5 document contains 132 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n20http://linked.opendata.cz/resource/drugbank/drug/DB00622/identifier/bindingdb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00622/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00622/identifier/pubchem-substance/
foafhttp://xmlns.com/foaf/0.1/
n32http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n27http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00622/identifier/drugbank/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00622/identifier/iuphar/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00622/identifier/guide-to-pharmacology/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00622/identifier/national-drug-code-directory/
n30http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n26http://www.rxlist.com/cgi/generic/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00622/identifier/chemspider/
n28http://linked.opendata.cz/resource/drugbank/patent/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n31http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n25http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00622/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00622/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00622/identifier/kegg-compound/
n22http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00622
rdf:type
n3:Drug
n3:description
A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]
n3:dosage
n27:271B58D9-363D-11E5-9242-09173F13E4C5 n27:271B58DA-363D-11E5-9242-09173F13E4C5 n27:271B58DB-363D-11E5-9242-09173F13E4C5 n27:271B58DC-363D-11E5-9242-09173F13E4C5 n27:271B58D5-363D-11E5-9242-09173F13E4C5 n27:271B58D6-363D-11E5-9242-09173F13E4C5 n27:271B58D7-363D-11E5-9242-09173F13E4C5 n27:271B58D8-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
8.6 hours
n3:indication
Used for the management of patients with chronic stable angina and for the treatment of hypertension.
n3:manufacturer
n4:271B58B8-363D-11E5-9242-09173F13E4C5 n4:271B58B5-363D-11E5-9242-09173F13E4C5 n4:271B58B6-363D-11E5-9242-09173F13E4C5 n4:271B58B4-363D-11E5-9242-09173F13E4C5 n4:271B58BF-363D-11E5-9242-09173F13E4C5 n4:271B58C0-363D-11E5-9242-09173F13E4C5 n4:271B58BD-363D-11E5-9242-09173F13E4C5 n4:271B58BE-363D-11E5-9242-09173F13E4C5 n4:271B58BB-363D-11E5-9242-09173F13E4C5 n4:271B58BC-363D-11E5-9242-09173F13E4C5 n4:271B58B9-363D-11E5-9242-09173F13E4C5 n4:271B58BA-363D-11E5-9242-09173F13E4C5 n4:271B58B7-363D-11E5-9242-09173F13E4C5
owl:sameAs
n19:DB00622 n30:DB00622
dcterms:title
Nicardipine
adms:identifier
n6:Nicardipine n10:46504482 n11:PA450620 n12:4474 n13:C07264 n14:0703-8315-03 n15:2559 n16:2559 n17:DB00622 n20:50017085 n21:4319
n3:mechanismOfAction
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
n3:packager
n4:271B58A9-363D-11E5-9242-09173F13E4C5 n4:271B58AA-363D-11E5-9242-09173F13E4C5 n4:271B58A7-363D-11E5-9242-09173F13E4C5 n4:271B58A8-363D-11E5-9242-09173F13E4C5 n4:271B58AD-363D-11E5-9242-09173F13E4C5 n4:271B58AE-363D-11E5-9242-09173F13E4C5 n4:271B58AB-363D-11E5-9242-09173F13E4C5 n4:271B58AC-363D-11E5-9242-09173F13E4C5 n4:271B58B1-363D-11E5-9242-09173F13E4C5 n4:271B58B2-363D-11E5-9242-09173F13E4C5 n4:271B58AF-363D-11E5-9242-09173F13E4C5 n4:271B58B0-363D-11E5-9242-09173F13E4C5 n4:271B58B3-363D-11E5-9242-09173F13E4C5 n4:271B58A1-363D-11E5-9242-09173F13E4C5 n4:271B58A2-363D-11E5-9242-09173F13E4C5 n4:271B58A0-363D-11E5-9242-09173F13E4C5 n4:271B58A5-363D-11E5-9242-09173F13E4C5 n4:271B58A6-363D-11E5-9242-09173F13E4C5 n4:271B58A3-363D-11E5-9242-09173F13E4C5 n4:271B58A4-363D-11E5-9242-09173F13E4C5
n3:patent
n28:5164405 n28:7612102
n3:routeOfElimination
Nicardipine has been shown to be rapidly and extensively metabolized by the liver.
n3:synonym
Nicardipino Cardene Nicardipinum
n3:toxicity
Oral LD<sub>50</sub> Rat = 184 mg/kg, Oral LD<sub>50</sub> Mouse = 322 mg/kg
n3:volumeOfDistribution
* 8.3 L/kg
n8:hasAHFSCode
n9:24-28-08
n3:foodInteraction
Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product. Take without regard to meals.
n3:proteinBinding
>95%
n3:salt
n3:synthesisReference
Takashi Sonobe, Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Satoru Yoneya, Chiharu Yamada, Yukio Kubota, "Composition for long acting nicardipine preparation and process of producing the composition." U.S. Patent US4758437, issued March, 1979.
n31:hasConcept
n32:M0014820
foaf:page
n25:nicardipine.html n26:nicardipine.htm
n3:IUPAC-Name
n7:271B58E1-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B58E7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B58E6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B58E3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B58E4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B58E5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B58F6-363D-11E5-9242-09173F13E4C5 n7:271B58DF-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B58F8-363D-11E5-9242-09173F13E4C5 n7:271B58E0-363D-11E5-9242-09173F13E4C5 n7:271B58DD-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B58DE-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n22:C08CA04
n3:H-Bond-Acceptor-Count
n7:271B58ED-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B58EE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B58E8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B58E9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B58EB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B58EA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B58EC-363D-11E5-9242-09173F13E4C5
n3:absorption
While nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
55985-32-5
n3:category
n3:clearance
* 0.4 L/hr∙kg [Following infusion]
n3:containedIn
n23:271B58CB-363D-11E5-9242-09173F13E4C5 n23:271B58CC-363D-11E5-9242-09173F13E4C5 n23:271B58C9-363D-11E5-9242-09173F13E4C5 n23:271B58CA-363D-11E5-9242-09173F13E4C5 n23:271B58CF-363D-11E5-9242-09173F13E4C5 n23:271B58D0-363D-11E5-9242-09173F13E4C5 n23:271B58CD-363D-11E5-9242-09173F13E4C5 n23:271B58CE-363D-11E5-9242-09173F13E4C5 n23:271B58D1-363D-11E5-9242-09173F13E4C5 n23:271B58D2-363D-11E5-9242-09173F13E4C5 n23:271B58D3-363D-11E5-9242-09173F13E4C5 n23:271B58C3-363D-11E5-9242-09173F13E4C5 n23:271B58C4-363D-11E5-9242-09173F13E4C5 n23:271B58D4-363D-11E5-9242-09173F13E4C5 n23:271B58C1-363D-11E5-9242-09173F13E4C5 n23:271B58C2-363D-11E5-9242-09173F13E4C5 n23:271B58C7-363D-11E5-9242-09173F13E4C5 n23:271B58C8-363D-11E5-9242-09173F13E4C5 n23:271B58C5-363D-11E5-9242-09173F13E4C5 n23:271B58C6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B58F2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B58F4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B58F5-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B58F7-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B58F1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B58F0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B58F3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B58E2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B58EF-363D-11E5-9242-09173F13E4C5